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1. Introduction 
There hds been constderable interest during the 
last few years m the area of drug targeting as it has 
become clear that m order to achieve optimal condr- 
trons for the action of pharmacologtcdl agents mter- 
action with non-target sites should be mmunrzed [ l] 
Investrgdtrons to complex antrtumour drugs with 
antibodies are noteworthy m this context [2] Smular- 
ly, the use of hposomes as carrters deserves mention 
as they are predommantly transported mto the liver 
and spleen [ 1 ] 
While studying the use of magnetic carriers in 
affimty chromatography [3] rt occurred to us that 
magnetrc material might dlso be used as support for 
drugs which could be brought to the target site wrth 
the aid of a magnetic field [4] Apart from mmlmrz- 
mg mteractrons with non-target sites such a specific 
location would allow a high concentration of the drug 
to be used and would extend the time of exposure at 
the site 
In the followmg we wash to report on the prepara- 
tion and apphcatron of such mdgnetrc drug-carrying 
materials 
2. Materials and methods 
2 1 Materzals 
Acid-hydrolysed starch with mol wt -40 000 was 
used m all experiments The starch (Farmex PSI @‘) 
was a gift from AB Stadex, Malmo H-D-Val-Leu- 
Lys-pNA was obtained from Kabr Dragnostrka, 
Stockholm 
The emulgator Gafac PE-5 lo@ (an ester of phos- 
phoric acid) as well as the carbonyl-non powder 
112 
(dram 2-3 pm cont~mmg a mmm~um of 99 5% iron) 
were a gift from AB Svenska GAF, Stockholm, (GAF, 
140 West 5 1 Street. New York, NY 10020) Powdered 
magnetite m aqueous slurry (-45% solids with dram 
0 05 ~111, type 4 100) was from Wrtght Industrtes, 
Brooklyn, New York 
(‘251)Albumm, type IM-17P, with dn activity of 
50 &i/ml (30 mg/ml) ds well as [2-14C]etl~anolamine 
wrth an activity of 44 mCi/mmol were from the 
RadrochemrcJ Centre, Amersham 
cu-Amyldse with spec act 20 pKat/mg was 
obtained from Sigma, St Lotus, MO Plasmm was a 
gift from NOVO A/S, Copenhagen. with spec act 
3 3 NU/mg (NOVO units One umt 1s defined as the 
amount of enzyme that m 20 mm dt pH 7 5 and 
35 5°C gives rrse to the formatton of perchlorrc acrd- 
soluble degradation products with an AZ7snm of 1) 
2 3 Preparatzorz of vzagrzetzc mzcrosp/zercs 
In a typical procedure 10 ml water were mixed 
with 6 g starch and 5 g carbonyllrron m a beaker 
The slurry was heated under gentle agitation and 
dllowed to boll for a few seconds to ensure complete 
solubrhzatron of the starch At >9O”C, the starch- 
carbonyl -iron slurry was slowly poured mto 100 ml 
stirred toluene at room temperature contammg the 
dissolved emulgator Gafac PE-5 10 at 1% The speed 
of sttrrmg was adjusted according to the desired size 
of the mrcrospheres (e g ,600O rev /mm resulted m 
beads of -3-l 5 pm dram ) Immediately thereafter 
the mixture was cooled m an ice bath (still under 
strrrmg) to 10°C Recently we found that on mcreas- 
mg the amount of carbonyllrron IO-fold, a high 
yield of beads (95%) with a narrow size dtstrrbutron 
of 2-5 pm could be obtained 
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For non-magnetic starch microspheres the same 
amounts and procedure as for magnetic microspheres 
was applied except for omission of the iron particles. 
In the washing procedure with acetone, the micro- 
spheres were allowed to sediment and when washing 
with water, centrifugation was used. When the 
precipitate turned too hard, a quick sonication resus- 
pended the microspheres. 
The magnetic microspheres obtained were trans- 
ferred to a 500 ml beaker containing 200 ml acetone 
and placed on an electromagnet. The supernatant was 
aspirated. The same procedure was repeated 4 times 
with equal amount of acetone followed by washing 
with water 6 times. 
When powdered magnetite was used the same 
procedure was followed except that 10 g powdered 
magnetite was used and that after boiling the slurry 
was sonicated for a few seconds to ensure complete 
resuspension of aggregated magnetite particles. 
The yield of beads in both cases was in general 
>90%. The microspheres were sieved through a nylon 
net with an av. diam. 10 pm; the amount of beads 
recovered from the sieving step was -lo-20%. The 
beads collected were then used in the subsequent 
experiments. 
2.3. Covalent coupling of compounds to the 
microspheres 
2.3.1. [2-r4C]Ethanolamine 
Activation according to the CNBr procedure [S] 
was for 7 min at pH 11 using 500 mg CNBr in 15 ml 
water and with 1 ml magnetic microspheres (carbonyl- 
iron), size 2- 15 ,um (not sieved preparation). Coupl- 
ing proceeded overnight at room temperature in 2 ml 
total vol. of 0.1 M NaHCOa containing 1 mg ethanol- 
amine (55 pg [14C]ethanolamine). For animal experi- 
ments 200 pl sieved magnetic microspheres (size 
2-10 pm, major fraction 3-5 pm) were activated with 
100 mg CNBr and 33 pg [“Clethanolamine was added 
for coupling. After coupling the microspheres were 
washed extensively in the sequence 0.1 M NaHCOa, 
1 mM HCl, 0.5 M NaCl and water until no radioactivity 
was found in the supernatants. 
2.3.2. (1251)Albumin 
Activation following the CNBr procedure was 
carried out for 7 min at pH 11 using 20 mg CNBr in 
15 ml water and with 200 ~1 magnetic microspheres 
(carbonyl-iron), size 2-10 pm, sieved, major frac- 
tion 3-5 ym. Coupling proceeded overnight in 10 ml 
0.1 M NaHCOa after addition of 100 1.11 ( 251)albumin 
preparation. 
2.3.3. Plasmin 
Magnetic microspheres (powdered magnetite) were 
activated with 200 mg CNBr in 15 ml water and with 
1 ml microspheres present. For coupling 3 mg 
plasmin were added (in 10 ml total vol.) and coupling 
proceeded overnight at 4°C in 0.1 M NaHCOa. 
2.3.4. Plasmin assay 
Microspheres (0.5 ml) were suspended in 10 ml 
50 mM Tris-HCl (pH 7.4) buffer containing 12 mM 
NaCl. Air was bubbled through the suspension to 
maintain mixing. The suspension was then pumped 
through a continuous-flow system essentially following 
the procedure for immunoassays in [6]. The modifica- 
tions introduced include the omission of the extra 
inlet and the use of one pump on each side of the 
membrane to obtain filtration. After obtaining 
equilibration of the system, 0.5 ml of the synthetic 
peptide substrate H-D-Val-Leu-Lys-pNA was 
added to give 1.2 mM final cont. Hydrolysis was 
continuously followed at 405 nm. 
2.4. Animal experiments 
Rabbits (2-4 kg) were anaesthetized with 
Nembutal@ through a catheter in the marginal ear 
vein. 
Magnetic microspheres (-100 ~1) suspended in 
3 ml 0.154 M NaCl, were then injected through the 
same catheter as the Nembutal@. The distal part of 
the opposite ear was placed in the gap of an electro- 
magnet (0.7 Tessla). The ear not placed in the magnet 
served as reference. 
After 10 min, a period shown to be sufficiently 
long to allow ‘location’ of the magnetic beads, the 
rabbits were killed by an overdose of Nembutal. The 
distal part of the ear (4 cm) was then cut off and 
placed in a gamma counter to measure the radio- 
activity emanating from the (1251)albumin coupled to 
magnetic microspheres that had been trapped in the 
ear. Alternatively, when injecting [14C]ethanolamine 
carrying magnetic microspheres the part of the ear 
directly lying within the area of the magnetic field 
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(-1 cm”) was cut out and dried Subsequently it was 
subjected to total combustion [7] and the radlo- 
activity of the trapped Ba14C03 was determmed 
2 5 Enzymlc dlgestlon of the mlcrospheres 
The nucrospheres were treated with oi-amyldse m 
0 15 M phosphate buffer (pH 7 4) measurmg reducing 
groups liberated by reduction of 3,5-dmltrosahcychc 
acid [8] The amount of enzyme added varied from 
3 nKat to 1 pKat/ml m the assay solution 
3. Results and discussion 
In our work we have applied as magnetic material 
carbonyl-iron (Z-3 pm). powdered magnetite 
(0 05 pm) [9] or a magnetic fluid called ferrofluld [3] 
(In prehmmary studies the latter material was kept 
entrapped m acrylate polymers to which &galactosldase 
was bound ) The predominant pdrt of our mvestlga- 
tlon mcludmg the animal expenments was carried out 
with entrapped carbonyl-non As the iron prepara- 
tion oxidized on long storage. we also later employed 
the same entrapping technique to powdered magnetite 
Apart from the fact that the latter preparations did 
not contam as much magnetic material, the properties 
of the beads obtained appeared identical Further 
studies with the latter preparations are m progress 
The polymers m which the magnetic material was 
entrapped conslsted of stdrch Starch was chosen as 
carrier as it 1s blocompatlble and also because the 
a-amylase capable of degrading starch IS present m 
the human body The magnetic material was entrapped 
m the beads as the starch was retrogrdded The term 
retrogradatlon describes changes occurring normally 
in starch on agemg which 1s basicdlly a crystalhzatlon 
process and mvolves hydrogen-bond formation 
between hydroxyl groups on adjacent starch molecules 
[lo] With heat treatment followed by quick coolmg 
such retrogrddation can rapldly be accomplished The 
beads obtained are relatively stable not requiring 
additional crosshnkmg which makes then prepara- 
tion easy (Beads made up of crosslmked starch have 
been described m [ 1 1,121 However, the addltlon of 
crosslmkmg agents such as eplchlorhydrm makes 
these preparations more hazardous and the procedure 
more comphcdted. though m [ 131 we found that 
somcation of the preparation during crosshnkmg 
resulted m beads of a narrow size dlstrlbutlon 
(2-5 pm) ) The magnetic properties of the beads 
obtained are excellent, dllowmg easy retrieval, employ- 
mg even wedk magnets The bead diameter could 
easily be varied by chdngmg m particular the stirring 
rate 
The two types of magnetic bedds obtained are 
shown m fig 1 In the beads contammg entrapped 
carbonyl-Iron the mdlvldual iron particles (dlam 
2-3 pm) can be dlstmgulshed whereas m the beads 
containing the far smaller magnetite particles (diam 
0 05 ~.lm) the latter cannot be vlsuahzed separately 
and appear as a dark area because of the limited 
resolution of light microscopes 
Fig 1 Photomlcrographs showmg magnetic muxospheres (dlam 50 pm) consisting of entrapped carbonyl-iron (left) and 
powdered magnetite (right) In the ammal studies the maJor fraction of the carbonyl-non-starch mlcrospheres applied was much 
smaller, essentially made up of one smgle uon particle covered with a l-2 pm layer of starch 
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3 .I. Covalent coupling to the magnetic starch 
microspheres 
As high molecular weight model substance 
(enzyme) we have chosen (1251)albumin and as low 
molecular weight model substance (low molecular 
weight drug) [‘4C]ethanolamine, both of which were 
coupled covalently to the support. No attempts were 
made to optimize the coupling conditions. With 
(1251)albumin 110 000 cpm/ml microspheres were 
found which corresponds to a coupling yield of 2% or 
0.04 mg albumin/ml microspheres. The relatively 10~ 
coupling yield is most likely due to steric hindrance 
exerted by the starch only permitting surface binding 
of the relatively large albumin molecule. 
In contrast, 45% of added ethanolamine was 
coupled, yielding 4.75 @mol/ml. 
In addition we also coupled covalently an enzyme, 
plasmin, to the magnetic microspheres. This enzyme 
was chosen because of its potential therapeutic value 
due to its reported activity in fibrinolysis of blood 
clots [14]. On the average the microspheres showed 
-10% of added total enzymic activity corresponding 
to 1 NU/ml wet gel. 
3.2. Animal experiments 
On injecting magnetic starch microspheres 
(carbonyl-iron) to which (1251)albumin had been 
coupled, enrichment of radioactivity was repeatedly 
observed in the ear to which the magnetic field had 
been applied, despite the fact that injection was 
carried out in the other ear which served as reference. 
Of the total radioactivity injected, only a minor frac- 
tion (0.3%) was ‘retrieved’ in the ‘magnetic’ ear. 
However, considering that the major fraction (-80%) 
of the injected beads (2-l 0 urn, major fraction 
3-5 pm) was trapped in the animals’ lungs this is not 
surprising. Studies are now in progress to obtain 
preparations with a very narrow size distribution as 
well as smaller microspheres containing entrapped 
magnetite powder. We also injected likewise coupled 
[l*‘I] thyroxine and found that enrichment in the 
‘magnetic’ ear compared to the blank ear was obtained 
on all occasions. However, as some leakage of the 
radioactive material in this particular experiment was 
continuously taking place no quantitative data are 
given here. 
Finally, [i4C]ethanolamine-carrying magnetic 
microspheres (total radioactivity of the 100 nl beads 
injected was 6 X 10’ dpm) were injected. Whereas 
25 15 dpm were found in the part of the ear to which 
a magnetic field had been applied only 370 dpm were 
found in the reference ear. 
In all animal experiments the enrichment factor 
between the ‘magnetic’ and ‘non-magnetic’ ear was 
4-8, in one animal an enrichment factor of 21 was 
obtained. Summarizing the results obtained, one can 
conclude that enrichment of the injected magnetic 
‘drug’carrying support can be accomplished with the 
application of an external magnetic field. 
From preliminary studies it is evident that the 
microspheres could be degraded by amylase. Applying 
a concentration of enzyme corresponding to that 
present in human blood, i.e., 3 nKat/ml, magnetic 
microspheres (not CNBr-activated) were dissolved 
within 2 h. In contrast, CNBr-activated microspheres 
were degraded only after application of far higher 
amylase concentrations (loo-times), which is probably 
due to higher crosslinking of the latter preparations. 
This could probably be compensated for in vivo by 
longer exposure to the enzyme. 
In the future we hope to demonstrate in in vivo 
studies how to locate and concentrate in a magnetic 
field drug-carrying magnetic microspheres, in particular 
plasmin for degradation of blood clots and cytotoxic 
drugs for tumour treatment. 
It will be necessary to investigate the strength of 
the magnetic field required to keep the iron prepara- 
tion in place. Reports in the literature indicate that it 
should be possible in principle to create strong enough 
magnetic fields to do this. Thus, studies on magnet- 
ically-controlled iron thrombosis in rabbits showed 
that it is possible to arrest injected iron particles in 
the blood stream [ 151. Similarly, the demonstration 
of a superconducting electromagnet being able to 
keep ferrosilicone particles in the arterial blood stream 
is noteworthy in this context [16]. 
Regarding the removal of injected microspheres, 
which is of importance in particular on long-term use, 
the following alternatives can be envisaged. The intact 
microspheres including the magnetic material are 
collected by application of a magnetic field across an 
extracorporeal vascular shunt device. If the micro- 
sphere is degraded by enzymes present in the body 
the magnetic material could be removed out of the 
body depending on its size either by the above 
approach or by excretion. Excretion seems possible in 
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particular for the small magnetite particles (0 05 I*m) 
used m this study 
In general, when using carriers m drug delivery, 
Ideally the followmg requirements should be met 
(1) The carrier should be blocompatlble, 1.e , non- 
toxic and non-lmmunogemc. 
(11) after reaching the target area the drug must be 
allowed to exhlblt its activity 
This can m principle be achieved by 
(1) 
(2) 
Enzymlc, chemical or phynco-chemical methods 
leading to controlled release of either a covalently 
or otherwise bound, e g , entrapped or adsorbed 
drug 
In some cases the drug, m particular if It 1s of 
macromolecular size such as an enzyme, may 
exert its actlvlty even m its lmmoblllzed state m 
which case no release mechanism 1s required 
Starch has hitherto not been used as carrier of 
unmoblhzed blomolecules except, for Instance, as a 
pad for entrapped enzymes monitored m an enzyme 
electrode [7] or m an electrochemical cell [18] 
Compared to macroretlcular structures such as 
agarose, the total loading capacity seems to be lower 
and mlcroblal dlsmtegratlon may occur However, 
besides apphcatlons of the type described here where 
blocompatlble and hkewlse biodegradable polymers 
are advantageous, starch as a support may be useful 
also for other applications, partly because of its low 
cost Thus, the starch microsphere preparations 
described, m particular those containing magnetite, 
appear to represent alternatives to the described 
magnetic supports applied m cell separation [9], 
enzyme-immunoassay [191 and smnlar areas 
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